| Not Yet Recruiting | A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A Myel NCT07463820 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT NCT07254793 | University of Arizona | Phase 1 |
| Not Yet Recruiting | Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; NCT07153497 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of G NCT06996119 | City of Hope Medical Center | Phase 1 |
| Recruiting | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Vir NCT07020533 | City of Hope Medical Center | Phase 1 |
| Not Yet Recruiting | Study of an Innovative Therapy Using CAR-T Cells Targeting IL-1RAP in Patients With High-Risk Myelodysplastic NCT07455500 | University Hospital, Grenoble | N/A |
| Recruiting | A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate NCT07422480 | Takeda | Phase 3 |
| Not Yet Recruiting | CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML or HR-MDS NCT07347418 | University of Colorado, Denver | Phase 1 |
| Recruiting | Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic NCT07107126 | Remedy Plan, Inc. | Phase 1 |
| Recruiting | FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia NCT07283094 | Montefiore Medical Center | Phase 1 |
| Not Yet Recruiting | Study of NK Cells in the Monitoring of Patients With Acute Leukemia or Myelodysplasia NCT07249476 | Nantes University Hospital | — |
| Recruiting | Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibros NCT06781099 | Hospices Civils de Lyon | N/A |
| Recruiting | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and NCT07285044 | Mayo Clinic | Phase 2 |
| Recruiting | Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acut NCT07228273 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and NCT07046078 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients Wi NCT06484062 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid NCT06287944 | City of Hope Medical Center | Phase 1 |
| Recruiting | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher NCT06577441 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT NCT06984536 | Peking University People's Hospital | Phase 2 |
| Recruiting | Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation NCT06793410 | Vastra Gotaland Region | Phase 2 |
| Not Yet Recruiting | Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients NCT06900088 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Vers NCT06815003 | City of Hope Medical Center | Phase 2 |
| Recruiting | Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant NCT06265584 | University of Alabama at Birmingham | Phase 2 |
| Recruiting | Feasibility and Safety of Exercise in Patients With Low-risk Myeloid Cancers and Precursor Conditions NCT06773871 | Rigshospitalet, Denmark | N/A |
| Recruiting | A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malig NCT06616636 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Do NCT06498973 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia NCT06944119 | Tel-Aviv Sourasky Medical Center | — |
| Recruiting | Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell T NCT06543381 | City of Hope Medical Center | Phase 1 |
| Recruiting | A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies NCT06820268 | NovaOnco Therapeutics Co., Ltd. | Phase 1 |
| Withdrawn | Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT NCT03939585 | Leland Metheny | Phase 1 |
| Withdrawn | Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS NCT05823480 | City of Hope Medical Center | Phase 1 |
| Suspended | DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hem NCT06492707 | Fred Hutchinson Cancer Center | Phase 1 |
| Recruiting | Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy NCT06510868 | University Health Network, Toronto | — |
| Recruiting | Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hig NCT06013423 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and NCT06128070 | City of Hope Medical Center | Phase 2 |
| Recruiting | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Pat NCT06059391 | City of Hope Medical Center | Phase 2 |
| Recruiting | Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Child NCT06756152 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 2 / Phase 3 |
| Recruiting | MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Tr NCT05564390 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoc NCT06419634 | Bristol-Myers Squibb | Phase 1 |
| Recruiting | Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leu NCT06195891 | City of Hope Medical Center | Phase 1 |
| Recruiting | Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial NCT06355583 | Imperial College London | Phase 2 |
| Recruiting | A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic S NCT06073860 | Bristol-Myers Squibb | — |
| Recruiting | Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, NCT06063486 | University of Southern California | Phase 2 |
| Recruiting | A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2 NCT06329999 | Ruijin Hospital | N/A |
| Active Not Recruiting | Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagno NCT06034470 | Fred Hutchinson Cancer Center | Phase 1 |
| Active Not Recruiting | A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia NCT07052006 | Halia Therapeutics, Inc. | Phase 2 |
| Recruiting | Revisiting the Universal Donor: Does Exposure to O Blood Products Affect Patient Outcomes? NCT04859218 | McMaster University | N/A |
| Recruiting | A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndro NCT05693909 | Pharmacosmos A/S | Phase 2 |
| Recruiting | High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) NCT07205523 | Yigeng Cao,MD,PhD | — |
| Recruiting | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer NCT05969860 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the NCT04994808 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodys NCT05600894 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, a NCT05457556 | Children's Oncology Group | Phase 3 |
| Active Not Recruiting | Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome NCT05564650 | Thomas Jefferson University | Phase 1 |
| Completed | GITMO AML/MDS-Relapse Registry Study NCT06790680 | Gruppo Italiano Trapianto di Midollo Osseo | — |
| Active Not Recruiting | Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patien NCT05364762 | City of Hope Medical Center | Phase 2 |
| Terminated | Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers NCT04083170 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin NCT04802161 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Trea NCT05139004 | City of Hope Medical Center | Phase 1 |
| Unknown | A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS NCT05448599 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT NCT05453552 | Nanfang Hospital, Southern Medical University | Phase 2 / Phase 3 |
| Active Not Recruiting | Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic NCT05316701 | Orca Biosystems, Inc. | Phase 3 |
| Active Not Recruiting | Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Ac NCT03399773 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With NCT04726241 | PedAL BCU, LLC | Phase 1 / Phase 2 |
| Completed | Off-the-shelf NK Cells + SCT for Myeloid Malignancies NCT05115630 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndr NCT05823714 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | Two Step Haplo With Radiation Conditioning NCT05031897 | Thomas Jefferson University | Phase 2 |
| Recruiting | Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS NCT04708054 | M.D. Anderson Cancer Center | Phase 2 / Phase 3 |
| Unknown | A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy o NCT05061147 | Maxinovel Pty., Ltd. | Phase 1 / Phase 2 |
| Recruiting | ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutate NCT05010122 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia NCT04734990 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test NCT04635384 | CareDx | — |
| Active Not Recruiting | A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome NCT04900350 | Akeso | Phase 1 / Phase 2 |
| Terminated | MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies NCT04762875 | Ensoma | Phase 2 |
| Completed | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candid NCT05972577 | Ohio State University Comprehensive Cancer Center | N/A |
| Withdrawn | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis Af NCT03602898 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without G NCT04842604 | Pfizer | Phase 3 |
| Terminated | A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate NCT04691141 | Shanghai Antengene Corporation Limited | Phase 1 / Phase 2 |
| Active Not Recruiting | Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neop NCT04279847 | Incyte Corporation | Phase 1 |
| Active Not Recruiting | Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders NCT04761770 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hemat NCT04195633 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome NCT04655755 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Unknown | G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo NCT04713956 | Nanfang Hospital, Southern Medical University | Phase 2 / Phase 3 |
| Recruiting | CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic S NCT04493164 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | National Longitudinal Cohort of Hematological Diseases NCT04645199 | Institute of Hematology & Blood Diseases Hospital, China | — |
| Active Not Recruiting | Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study NCT04537871 | City of Hope Medical Center | — |
| Completed | Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplas NCT04339101 | City of Hope Medical Center | Phase 2 |
| Terminated | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malig NCT03272633 | Rutgers, The State University of New Jersey | EARLY_Phase 1 |
| Completed | Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced M NCT04146038 | Rutgers, The State University of New Jersey | Phase 2 |
| Completed | Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization NCT04439006 | Jennifer Woyach | Phase 1 |
| Completed | 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II NCT03941769 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | SARS-CoV-2 Donor-Recipient Immunity Transfer NCT04666025 | City of Hope Medical Center | — |
| Recruiting | A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patien NCT04239157 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies NCT04227847 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferativ NCT04493138 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Suspended | Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) o NCT04278768 | Curis, Inc. | Phase 1 / Phase 2 |
| Recruiting | Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or My NCT03969446 | City of Hope Medical Center | Phase 1 |
| Recruiting | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloprolif NCT04282187 | University of Washington | Phase 2 |
| Active Not Recruiting | TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT NCT04281199 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Pat NCT04262843 | City of Hope Medical Center | Phase 2 |
| Recruiting | A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic S NCT04243785 | Edgewood Oncology Inc. | Phase 1 |
| Withdrawn | Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated D NCT03066466 | Loyola University | Phase 3 |
| Active Not Recruiting | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation NCT04060277 | City of Hope Medical Center | Phase 2 |
| Recruiting | Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Reco NCT04167696 | Celyad Oncology SA | Phase 1 |
| Recruiting | Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukem NCT03970096 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome NCT04160052 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Ac NCT04079296 | Astellas Pharma Global Development, Inc. | Phase 1 / Phase 2 |
| Completed | PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome NCT04022785 | M.D. Anderson Cancer Center | Phase 1 |
| Withdrawn | ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Le NCT04013880 | Vanderbilt-Ingram Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant NCT03622788 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | AZD6738 for Patients With Progressive MDS or CMML NCT03770429 | Massachusetts General Hospital | Phase 1 |
| Unknown | Early Palliative Care for Patients With Haematological Malignancies NCT03800095 | University Hospital, Clermont-Ferrand | Phase 3 |
| Recruiting | A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Tr NCT03739502 | University of Rochester | Phase 2 |
| Active Not Recruiting | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT03862157 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Bloo NCT03438344 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or NCT03672539 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leuk NCT03661307 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML NCT03365661 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Re NCT03600155 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndr NCT03630991 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Resiliency in Older Adults Undergoing Bone Marrow Transplant NCT04188678 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | — |
| Recruiting | Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 G NCT03683433 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Tran NCT03560752 | City of Hope Medical Center | Phase 1 |
| Terminated | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractor NCT03465540 | Amgen | Phase 1 |
| Suspended | Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treatin NCT03494569 | City of Hope Medical Center | Phase 1 |
| Completed | Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrom NCT03303066 | Kyntra Bio | Phase 2 / Phase 3 |
| Completed | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 NCT02890758 | Brenda Cooper, MD | Phase 1 |
| Completed | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelo NCT03358719 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malig NCT03471260 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodyspl NCT03337451 | Opsona Therapeutics Ltd. | Phase 1 / Phase 2 |
| Recruiting | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After NCT03326921 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Pat NCT03092674 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Terminated | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed NCT03404193 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Pa NCT03333486 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome NCT03359460 | University of California, Davis | Phase 1 |
| Terminated | Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentica NCT02999854 | Kiadis Pharma | Phase 3 |
| Completed | Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Hi NCT03268954 | Takeda | Phase 3 |
| Completed | Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome NCT03047993 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Unknown | Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome NCT03094637 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignanc NCT04484532 | Roswell Park Cancer Institute | EARLY_Phase 1 |
| Completed | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients W NCT03096782 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Study of SyB C-1101 in Patients With Myelodysplastic Syndrome NCT03495167 | SymBio Pharmaceuticals | Phase 1 |
| Terminated | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelate NCT03246906 | Fred Hutchinson Cancer Center | Phase 2 |
| Withdrawn | Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients NCT02923986 | Bio-Path Holdings, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus H NCT03192397 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer NCT03154190 | Stanford University | N/A |
| Terminated | Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azaci NCT02929498 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Withdrawn | Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study NCT03086252 | Emory University | N/A |
| Unknown | DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess NCT03356080 | Shanghai Tong Ren Hospital | Phase 2 |
| Recruiting | SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk My NCT03113643 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients Wi NCT02936752 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and NCT03150004 | Medical College of Wisconsin | Phase 2 |
| Terminated | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia NCT03195010 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in P NCT03128359 | City of Hope Medical Center | Phase 2 |
| Completed | Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms NCT03072043 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Completed | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep NCT02722668 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma NCT02743611 | Bellicum Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemi NCT03017820 | Mayo Clinic | Phase 1 |
| Completed | Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Le NCT03019939 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent NCT02943668 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide NCT03088709 | Loyola University | Phase 2 |
| Completed | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT02960646 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, NCT02728050 | University of Washington | Phase 1 / Phase 2 |
| Active Not Recruiting | Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomon NCT02935361 | University of Southern California | Phase 1 / Phase 2 |
| Completed | Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls NCT02809222 | University Hospital, Tours | N/A |
| Completed | A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Maligna NCT02842827 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | Phase 1 / Phase 2 |
| Completed | Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grad NCT02756572 | University of Washington | Phase 2 |
| Completed | A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or My NCT02807558 | Syros Pharmaceuticals | Phase 2 |
| Terminated | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Pa NCT02877082 | Emory University | Phase 2 |
| Completed | Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery NCT02767388 | University of Nebraska | — |
| Completed | Epigenetics, Vitamin C and Abnormal Hematopoiesis - Pilot Study NCT02877277 | Rigshospitalet, Denmark | N/A |
| Active Not Recruiting | Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer U NCT02861417 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS NCT02732184 | Aeglea Biotherapeutics | Phase 2 |
| Unknown | Effect of Chemotherapy vs No Chemotherapy Pre-transplant to MDS Undergoing Allo-HSCT NCT02850822 | Nanfang Hospital, Southern Medical University | — |
| Terminated | Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation NCT02750254 | Washington University School of Medicine | Phase 1 |
| Completed | Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplasti NCT02684162 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Phase 1/2 Study of CG200745 PPA for Myelodysplastic Syndrome NCT02737462 | CrystalGenomics, Inc. | Phase 1 / Phase 2 |
| Terminated | A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myel NCT02663752 | Novartis Pharmaceuticals | Phase 2 |
| Recruiting | Personalized NK Cell Therapy in CBT NCT02727803 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodys NCT02676323 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 NCT02719574 | Forma Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo NCT02744742 | Nanfang Hospital, Southern Medical University | Phase 2 / Phase 3 |
| Completed | Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML NCT02750995 | Daniel El Fassi | Phase 1 |
| Completed | Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplan NCT02639559 | Washington University School of Medicine | Phase 2 |
| Completed | Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation NCT02719821 | University of Wisconsin, Madison | N/A |
| Terminated | A Study of PLX51107 in Advanced Malignancies NCT02683395 | Plexxikon | Phase 1 |
| Recruiting | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and S NCT02508038 | University of Wisconsin, Madison | Phase 1 |
| Active Not Recruiting | Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) NCT02494167 | Baylor College of Medicine | Phase 1 |
| Terminated | Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Un NCT02706899 | Seagen Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in NCT02521493 | Children's Oncology Group | Phase 3 |
| Terminated | Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA NCT02562443 | Traws Pharma, Inc. | Phase 3 |
| Withdrawn | Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome NCT02783547 | SymBio Pharmaceuticals | Phase 1 |
| Completed | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malig NCT02556931 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients Wi NCT02566304 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Active Not Recruiting | Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV a NCT02506933 | City of Hope Medical Center | Phase 2 |
| Withdrawn | Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients NCT02431351 | Karyopharm Therapeutics Inc | Phase 2 |
| Completed | Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplanta NCT02598752 | Memorial Sloan Kettering Cancer Center | — |
| Completed | CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies NCT02678338 | Gilead Sciences | Phase 1 |
| Completed | Reduced Intensity Conditioning Transplant Using Haploidentical Donors NCT02581007 | Northside Hospital, Inc. | Phase 2 |
| Completed | Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Al NCT02500550 | Kiadis Pharma | Phase 2 |
| Completed | Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and NCT02447666 | Celgene | Phase 2 |
| Terminated | IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leuke NCT02508324 | Weill Medical College of Cornell University | Phase 2 |
| Active Not Recruiting | Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome NCT02530463 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodyspl NCT02485535 | University of Chicago | Phase 1 |
| Completed | Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies NCT02543879 | Forma Therapeutics, Inc. | Phase 1 |
| Terminated | A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies NCT02520427 | Amgen | Phase 1 |
| Terminated | Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies NCT02381548 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH NCT02492737 | Agios Pharmaceuticals, Inc. | Phase 1 |
| Completed | Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and A NCT02464657 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplan NCT02458235 | University of California, San Francisco | Phase 2 |
| Completed | CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Tr NCT02424968 | Robert Lowsky | Phase 2 |
| Completed | Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy NCT02487069 | Nanfang Hospital, Southern Medical University | N/A |
| Completed | Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies NCT02396134 | City of Hope Medical Center | Phase 2 |
| Unknown | Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) NCT02717884 | Michael Luebbert | Phase 1 / Phase 2 |
| Completed | Study of DSP-7888 in Patients With Myelodysplastic Syndrome NCT02436252 | Sumitomo Pharma Co., Ltd. | Phase 1 / Phase 2 |
| Completed | A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients NCT02367456 | Pfizer | Phase 1 |
| Completed | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Di NCT02397720 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Study of Clinical Efficacy and Safety of Tosedostat in MDS NCT02452346 | Weill Medical College of Cornell University | Phase 2 |
| Completed | Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands NCT02203825 | Celyad Oncology SA | Phase 1 |
| Completed | Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation NCT02312102 | Massachusetts General Hospital | Phase 1 |
| Terminated | GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conv NCT02360111 | Memorial Sloan Kettering Cancer Center | N/A |
| Terminated | Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid L NCT02226497 | Fred Hutchinson Cancer Center | N/A |
| Completed | A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome NCT02363491 | Opsona Therapeutics Ltd. | Phase 1 / Phase 2 |
| Suspended | Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome NCT01010373 | BioMAS Ltd | Phase 2 |
| Completed | Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int NCT02279654 | Celgene | — |
| Completed | Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies NCT02566395 | Northwell Health | Phase 3 |
| Completed | Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrom NCT02000154 | SymBio Pharmaceuticals | Phase 1 |
| Terminated | Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogeno NCT02319369 | Daiichi Sankyo | Phase 1 |
| Completed | Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Tr NCT02129582 | Case Comprehensive Cancer Center | Phase 1 |
| Terminated | Blood Samples to Identify Biomarkers of Busulfan NCT02291965 | Fred Hutchinson Cancer Center | — |
| Completed | Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic NCT02296242 | BioMed Valley Discoveries, Inc | Phase 1 / Phase 2 |
| Unknown | Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations NCT02272478 | Cardiff University | Phase 2 / Phase 3 |
| Completed | Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase NCT02103478 | Astex Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in NCT02250937 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord NCT01930162 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Occupational Status and Hematological Disease NCT02057185 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Completed | Iron Overload and Transient Elastography in Patients With Myelodysplastic Syndrome NCT02262312 | Zealand University Hospital | — |
| Completed | Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilic NCT02188290 | Kiadis Pharma | — |
| Completed | Nonmyeloablative Haploidentical Transplant Followed by MLN9708 NCT02169791 | Northside Hospital, Inc. | Phase 2 |
| Completed | Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention NCT01951885 | Case Comprehensive Cancer Center | Phase 3 |
| Completed | Adoptive Transfer of Haplo-identical DLI for AML and MDS NCT02046122 | Duke University | Phase 1 / Phase 2 |
| Completed | Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk My NCT02121418 | University of Washington | N/A |
| Terminated | Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) NCT02181699 | Kyowa Kirin, Inc. | Phase 1 |
| Completed | Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome NCT02117219 | MedImmune LLC | Phase 1 |
| Recruiting | Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk NCT02115295 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies NCT02129101 | Mayo Clinic | Phase 1 |
| Withdrawn | Three Dosing Schedules of Oral Rigosertib in MDS Patients NCT02075034 | Traws Pharma, Inc. | Phase 1 |
| Completed | Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leuke NCT01904136 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant NCT02065869 | Bellicum Pharmaceuticals | Phase 1 / Phase 2 |
| Unknown | Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome NCT02123836 | National University Hospital, Singapore | Phase 1 |
| Completed | Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in R NCT02083250 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients NCT01951430 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Active Not Recruiting | Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Le NCT01885689 | City of Hope Medical Center | Phase 2 |
| Unknown | Platelet Response During the Second Cycle of Decitabine Can Predict Response and Survival for Myelodysplastic NCT02045654 | Samsung Medical Center | — |
| Terminated | AHN-12 Biodistribution in Advanced Leukemia NCT01207076 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS NCT02018926 | Mirati Therapeutics Inc. | Phase 1 / Phase 2 |
| Completed | Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. NCT02017457 | Carlos Graux, MD, PhD | Phase 2 |
| Terminated | Phase I Study of Milatuzumab for Graft Versus Host Disease NCT01663766 | Gilead Sciences | Phase 1 |
| Active Not Recruiting | Evaluation of 3 Different Doses of IV Busulfan NCT01985061 | Institut Paoli-Calmettes | Phase 2 |
| Completed | Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond t NCT01993641 | Helsinn Healthcare SA | Phase 2 |
| Completed | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) NCT01953692 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplant NCT01634217 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Unknown | Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Imm NCT02007811 | University of Erlangen-Nürnberg Medical School | Phase 1 / Phase 2 |
| Unknown | Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leuke NCT01894477 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy NCT01980056 | Weill Medical College of Cornell University | Phase 1 / Phase 2 |
| Unknown | Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnos NCT02330692 | Yonsei University | — |
| Completed | Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis NCT02065154 | University of Alabama at Birmingham | Phase 2 |
| Completed | Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant NCT01812252 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrom NCT02002936 | SymBio Pharmaceuticals | Phase 1 |
| Completed | Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine NCT01926587 | Traws Pharma, Inc. | Phase 1 / Phase 2 |
| Completed | DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or A NCT01834248 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignan NCT01823198 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism NCT01855698 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Completed | Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome NCT01873703 | Helsinn Healthcare SA | Phase 2 |
| Completed | Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS NCT01700673 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine NCT01828346 | TetraLogic Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01664897 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who U NCT01602211 | Fred Hutchinson Cancer Center | Phase 3 |
| Completed | Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acut NCT01804101 | Fred Hutchinson Cancer Center | N/A |
| Unknown | NK Cells in Cord Blood Transplantation NCT01619761 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | The Effect of Combination Ultra Q10 and L-carnitine on the Course of Myelodysplastic Syndrome NCT02042482 | Kaplan Medical Center | Phase 2 / Phase 3 |
| Completed | A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor NCT01696461 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Completed | The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care NCT01566695 | Celgene | Phase 3 |
| Completed | Human Placental-Derived Stem Cell Transplantation NCT01586455 | New York Medical College | Phase 1 |
| Completed | Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS NCT02190695 | Fox Chase Cancer Center | Phase 2 |
| Unknown | A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome NCT02013102 | Cttq | Phase 4 |
| Completed | Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers NCT01597219 | University College, London | Phase 2 |
| Completed | Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic NCT01593670 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients Wi NCT01794299 | Kiadis Pharma | Phase 2 |
| Completed | Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplas NCT02014051 | SymBio Pharmaceuticals | Phase 1 |
| Terminated | Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine NCT01748240 | Groupe Francophone des Myelodysplasies | Phase 2 |
| Completed | Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy NCT01819558 | Institut Paoli-Calmettes | Phase 1 / Phase 2 |
| Unknown | Study of New RIC Regimen of BuFlu in Older and/or Intolerable Patients NCT01828619 | Peking University People's Hospital | — |
| Terminated | GVAX vs. Placebo for MDS/AML After Allo HSCT NCT01773395 | Dana-Farber Cancer Institute | Phase 2 |
| Terminated | Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syn NCT01795924 | Biosuccess Biotech Co., Ltd. | Phase 1 / Phase 2 |
| Completed | APG101 in Myelodysplastic Syndrome NCT01736436 | Apogenix GmbH | Phase 1 |
| Completed | Spanish Registry of Erythropoietic Stimulating Agents Study NCT01739452 | Grupo Español de Síndromes Mielodisplásicos | — |
| Terminated | Busulfan and Cyclophosphamide Followed By ALLO BMT NCT01685411 | Masonic Cancer Center, University of Minnesota | N/A |
| Completed | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies NCT01760655 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Pa NCT02085798 | Celgene | — |